The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis

Cell Death and Differentiation

Volumn 20, Issue 11, 2013, Pages 1485-1497

  Evangelou, K ^a   Bartkova, J ^b   Kotsinas, A ^a   Pateras, I S ^a   Liontos, M ^a   Velimezi, G ^a   Kosar, M ^b,c   Liloglou, T ^d   Trougakos, I P ^e   Dyrskjot, L ^f   Andersen, C L ^f   Papaioannou, M ^a   Drosos, Y ^g   Papafotiou, G ^h   Hodny, Z ^c   Sosa Pineda, B ^g   Wu, X R ⁱ   Klinakis, A ^h   Orntoft T ^f   Lukas, J ^b,j   Bartek, J ^b,c,k   Gorgoulis, V G ^a,h   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^d Roy Castle International Centre for Lung Cancer Research   (United Kingdom)

^e UNIVERSITY OF ATHENS   (Greece)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h BIOMEDICAL RESEARCH FOUNDATION   (Greece)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j University of Copenhagen   (Denmark)

^k PALACKÝ UNIVERSITY   (Czech Republic)

more..

Author keywords

ARF; carcinogenesis; DDR; E2F1; p16INK4A

Indexed keywords

ALTERNATIVE READING FRAME PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE H2AX; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER GROWTH; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE CHECKPOINT; FIBROBLAST; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SENESCENCE; SKIN CANCER; UPREGULATION; WNT SIGNALING PATHWAY;

AMINO ACID SEQUENCE; ANIMALS; CARCINOGENESIS; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA-BINDING PROTEINS; GENE EXPRESSION; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; ONCOGENES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84885427983     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.76     Document Type: Article

References (60)

1. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352-1355.
2. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006; 7: 667-677.
3. Gorgoulis VG, Halazonetis TD. Oncogene-induced senescence: the bright and dark side of the response. Curr Opin Cell Biol 2010; 22: 816-827.
4. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57.
5. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: a001883.
6. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
7. Bartkova J, Horejśi Z, Koed K, Krämer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
8. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-913.
9. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
10. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638-642.
11. Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B et al. Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res 2007; 67: 10899-10909.
12. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000; 10: 94-99.
13. Sherr CJ. Ink4-Arf locus in cancer and aging. Wiley Interdiscip Rev Dev Biol 2012; 1: 731-741.
14. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-374.
15. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
16. Branzei D, Foiani M. Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol 2010; 11: 208-219.
17. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-275.
18. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007; 117: 314-325.
19. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
20. Chen J, Huang XF. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009; 8: 1313-1317.
21. Wang QS, Papanikolaou A, Nambiar PR, Rosenberg DW. Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis. Mol Carcinog 2000; 28: 139-147.
22. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. N Engl J Med 1990; 323: 1228-1233.
23. Borinstein SC, Conerly M, Dzieciatkowski S, Biswas S, Washington MK, Trobridge P et al. Aberrant DNA methylation occurs in colon neoplasms arising in the azoxymethane colon cancer model. Mol Carcinog 2010; 49: 94-103.
24. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S et al. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 2006; 27: 1160-1168.
25. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999; 284: 770-776.
26. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33: 416-421.
27. Sarkar S, Jülicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR et al. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000; 60: 3862-3871.
28. Vikhanskaya F, Kei Lee M, Mazzoletti M, Broggini M, Sabapathy K. Cancer-derived p53 mutants suppress p53-target gene expression-potential mechanism for gain of function of mutant p53. Nucleic Acids Res 2007; 35: 2093-2104.
29. Schulz WA. Understanding urothelial carcinoma through cancer pathways. Int J Cancer 2006; 119: 1513-1518.
30. Makitie AA, Monni O. Molecular profiling of laryngeal cancer. Expert Rev Anticancer Ther 2009; 9: 1251-1260.
31. Yanofsky VR, Mercer SE, Phelps RG. Histopathological variants of cutaneous squamous cell carcinoma. J Skin Cancer 2011; 2011: 210813.
32. Rünger TM, Vergilis I, Sarkar P, DePinho RA, Sharpless NE. How disruption of cell cycle regulating genes might predispose to sun-induced skin cancer. Cell Cycle 2005; 4: 643-645.
33. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004; 64: 9027-9034.
34. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006; 66: 2116-2128.
35. Robertson KD, Jones PA. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol 1998; 18: 6457-6473.
36. Inoue K, Roussel MF, Sherr CJ. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 1999; 96: 3993-3998.
37. Berkovich E, Lamed Y, Ginsberg D. E2F and Ras synergize in transcriptionally activating p14ARF expression. Cell Cycle 2003; 2: 127-133.
38. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41: 2403-2414.
39. del Arroyo AG, El Messaoudi S, Clark PA, James M, Stott F, Bracken A et al. E2F-dependent induction of p14ARF during cell cycle re-entry in human T cells. Cell Cycle 2007; 6: 2697-2705.
40. Inoue K, Mallakin A, Frazier DP. Dmp1 and tumor suppression. Oncogene 2007; 26: 4329-4335.
41. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL et al. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395: 124-125.
42. Nikolaev SI, Sotiriou SK, Pateras IS, Santoni F, Sougioultzis S, Edgren H et al. A single-nucleotide substitution mutator phenotype revealed by exome sequencing of human colon adenomas. Cancer Res 2012; 72: 6279-6689.
43. Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013; 494: 492-496.
44. Bartek J, Mistrik M, Bartkova J. Thresholds of replication stress signaling in cancer development and treatment. Nat Struct Mol Biol 2012; 19: 5-7.
45. Bermejo R, Lai MS, Foiani M. Preventing replication stress to maintain genome stability: resolving conflicts between replication and transcription. Mol Cell 2012; 45: 710-718.
46. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17: 5001-5014.
47. Berkovich E, Ginsberg D. Ras induces elevation of E2F-1 mRNA levels. J Biol Chem 2001; 276: 42851-42856.
48. Haupt Y. Certainly no ARF terthought: oncogenic cooperation in ARF induction a key step in tumor suppression. Cell Cycle 2003; 2: 113-115.
49. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogen-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007; 9: 493-505.
50. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA et al. Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008; 14: 447-457.
51. Zhu D, Xu G, Ghandhi S, Hubbard K. Modulation of the expression of p16INK4a and p14ARF by hnRNP A1 and A2 RNA binding proteins: Implications for cellular senescence. J Cell Physiol 2002; 193: 19-25.
52. Lal A, Kim HH, Abdelmohsen K, Kuwano Y, Pullmann R Jr, Srikantan S et al. p16INK4a translation suppressed by miR-24. PLoS One 2008; 3: e1864.
53. Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 2003; 8: 131-144.
54. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW et al. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16Ink4a-p19 Arf pathway. Nat Genet 2004; 36: 343-350.
55. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12: 446-451.
56. Chang L, Karin M. Mammalian MAP kinase signaling cascades. Nature 2001; 410: 37-40.
57. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001; 409: 1067-1070.
58. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. BBA-Rev Cancer 2002; 1602: 73-87.
59. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16(INK4a) tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997; 15: 203-211.
60. Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004; 114: 1299-1307.